Beta-2 Glycoprotein 1 Antibodies, IgM, Serum
Use
This test is useful for evaluating patients with suspected antiphospholipid syndrome by identifying the presence of beta-2 glycoprotein 1 IgM antibodies. It is typically used as a first-line test when antiphospholipid syndrome is strongly suspected, in conjunction with cardiolipin antibodies (IgG and IgM) and lupus anticoagulant testing. Additionally, it assists in estimating the risk of thrombosis and/or pregnancy-related morbidity in patients with systemic lupus erythematosus.
Special Instructions
Not provided.
Limitations
The test may not completely distinguish between autoantibodies specific for antiphospholipid syndrome and those produced in response to infectious agents. Results may be highly variable across different commercial immunoassays. Documentation of persistent antibodies is required, as antibodies may be transiently produced. The presence of isolated and low levels of B2GPI IgM antibodies indicates a low risk for APS, and non-standard APS tests may be required if aPL tests are inconclusive.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
Beta-2 Glycoprotein 1 (B2GPI)
Protein
LOINC Codes
- 44449-7 - B2 Glycoprot1 IgM SerPl IA-aCnc
- 44449-7 - B2 Glycoprot1 IgM SerPl IA-aCnc
Result Turnaround Time
2-6 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.4 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, gross lipemia, heat-treated specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |